The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with ...

Chunhui Xu and her team leveraged the ISS National Laboratory ® for cardiac cell research to accelerate the development of cell-based regenerative therapies that could one day reverse heart damage.

Currently, CPR is performed on less than half of the people who are experiencing cardiac arrest in public before medical help arrives ... a cardiac emergency and every school in every county in Kansas ...

Kansas City does not have its own municipal detention center. In less than a month, voters will vote to decide how the proposed detention center will be funded. If Kansas City builds its detention ...

Kauffman Women’s Heart Center ... a Research 1 university, meaning it is in the top tier of research institutions in the country. It is the first and only R1 university in Kansas City, and ...

DeBakey Department of Surgery at Baylor College of Medicine, the QIMR Berghofer Medical Research Institute in Brisbane, Australia, and collaborating institutions report a groundbreaking discovery in ...

ARC, the global health innovation engine and transformation arm of the world-renowned Sheba Medical Center ... Innovation At the heart of this transformation is the ARC AI Center, a pioneering ...

Studies from the University of Michigan and the University of Colorado show a 24% increase in heart attacks the Monday after the time change, along with a rise in strokes two days later.

your chance of survival diminishes by 10%,” Region Government Relations Director for American Heart Association Kari Rinker said. “In some areas of Kansas, it can take 20 minutes for emergency ...

Bristol Myers Squibb is levering Fulcrum Therapeutics out of its life. MyoKardia, a biotech BMS bought in 2020, was working with Fulcrum to find cardiomyopathy targets but recently decided to end ...